Rein therapeutics granted two patents covering the novel formulation and administration methods of dry powder lti-03 for the treatment of respiratory diseases

Austin, texas , april 23, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the u.s. patent and trademark office (uspto) granted two new patents related to rein's lead product candidate, lti-03, a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling, which is administered through dry powder inhalation. u.s. patent no.
RNTX Ratings Summary
RNTX Quant Ranking